Cargando…

Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease

OBJECTIVES: To compare the risk of non‐skin cancer in LRRK2 mutation carriers and individuals with idiopathic Parkinson's disease (iPD), explore the age at which LRRK2 mutation carriers have cancer compared to iPD subjects, and clarify whether certain cancers are more closely associated with th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warø, Bjørg Johanne, Aasly, Jan O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853627/ https://www.ncbi.nlm.nih.gov/pubmed/29568677 http://dx.doi.org/10.1002/brb3.858

Ejemplares similares

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers
por: Wang, Shijie, et al.
Publicado: (2017)

Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort
por: Aasly, Jan O.
Publicado: (2021)

What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations?
por: Loeffler, David A., et al.
Publicado: (2019)

Metabolomic Profiling in LRRK2-Related Parkinson's Disease
por: Johansen, Krisztina K., et al.
Publicado: (2009)

Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation Carriers
por: Ouzren, Nassima, et al.
Publicado: (2019)

Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls
por: Alvarez-Castelao, Beatriz, et al.
Publicado: (2014)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Serotonin transporter binding and motor onset of Parkinson's disease in asymptomatic LRRK2 mutation carriers: a cross-sectional study
por: Wile, Daryl J, et al.
Publicado: (2017)

Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson’s Disease-Associated LRRK2 Gene Mutations
por: Loeffler, David A., et al.
Publicado: (2017)

Generalized dystonia without Parkinsonism in an LRRK2 carrier
por: Díaz-Feliz, Lola, et al.
Publicado: (2022)

Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
por: Aasly, Jan O., et al.
Publicado: (2015)

Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease
por: Gomes, Sara, et al.
Publicado: (2023)

Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease
por: San Luciano, Marta, et al.
Publicado: (2017)

Metabolic Profiling of CSF from People Suffering from Sporadic and LRRK2 Parkinson’s Disease: A Pilot Study
por: Yilmaz, Ali, et al.
Publicado: (2020)

Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease
por: Podlesniy, Petar, et al.
Publicado: (2019)

Transcriptome analysis in LRRK2 and idiopathic Parkinson’s disease at different glucose levels
por: Fernández-Santiago, Rubén, et al.
Publicado: (2021)

Differences in EEG Event-Related Potentials during Dual Task in Parkinson’s Disease Carriers and Non-Carriers of the G2019S-LRRK2 Mutation
por: Shkury, Eden, et al.
Publicado: (2023)

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson’s Disease
por: Ito, Genta, et al.
Publicado: (2023)

Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease
por: Cui, Shi-Shuang, et al.
Publicado: (2021)

Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study
por: Crotty, Grace F., et al.
Publicado: (2020)

Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers
por: Pont-Sunyer, Claustre, et al.
Publicado: (2015)

Novel recruitment strategy to enrich for LRRK2 mutation carriers
por: Foroud, Tatiana, et al.
Publicado: (2015)

Genetic association study of synphilin-1 in idiopathic Parkinson's disease
por: Myhre, Ronny, et al.
Publicado: (2008)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk
por: Lesniak, Robert K., et al.
Publicado: (2022)

Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers
por: Zhao, Ye, et al.
Publicado: (2018)

Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers
por: Gersel Stokholm, Morten, et al.
Publicado: (2020)

Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease
por: Garrido, Alicia, et al.
Publicado: (2022)

Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s disease
por: Soto, Marta, et al.
Publicado: (2023)

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts
por: Padmanabhan, Shalini, et al.
Publicado: (2020)

Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
por: Lai, Dongbing, et al.
Publicado: (2021)

Astrocytic atrophy as a pathological feature of Parkinson’s disease with LRRK2 mutation
por: Ramos-Gonzalez, Paula, et al.
Publicado: (2021)

The Role of LRRK2 in Neurodegeneration of Parkinson Disease
por: Rui, Qin, et al.
Publicado: (2018)

LRRK2 and the Endolysosomal System in Parkinson’s Disease
por: Erb, Madalynn L., et al.
Publicado: (2020)

LRRK2 at the Crossroad of Aging and Parkinson’s Disease
por: Hur, Eun-Mi, et al.
Publicado: (2021)

Pathological Functions of LRRK2 in Parkinson’s Disease
por: Jeong, Ga Ram, et al.
Publicado: (2020)

Modeling Parkinson’s disease in LRRK2 rodents
por: Domenicale, Chiara, et al.
Publicado: (2023)

LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
por: Bliederhaeuser, Corinna, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1sakgt6grfii1uvcrt0a973lic